| 81938-42-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• CAS: 81938-42-3
• 化学式: C22H23KNO4S2
• 分子量: 468.7
• InChiKey: NUJGKHLUMCDQQK-BQBHMPFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.66
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  125
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• ZOFENOPRIL CALCIUM
  申请人：Gore Vinayak G.

  公开号：US20090176860A1

  公开（公告）日：2009-07-09

  The present invention relates to zofenopril calcium form A substantially free of other forms of zofenopril calcium and to zofenopril calcium having a chemical purity of more than 98.5%. The present invention also relates to methods of preparing such zofenopril calcium. It further relates to compositions comprising such zofenopril calcium. Zofenopril calcium, (4S)-1-[(2S)-3-benzoylthio-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt, has the following structure:

  本发明涉及基本上不含其他形式的左非诺普利钙的左非诺普利钙A型，以及化学纯度超过98.5%的左非诺普利钙，还涉及制备此类左非诺普利钙的方法。此外，还涉及包含此类左非诺普利钙的组合物。左非诺普利钙，即(4S)-1-[(2S)-3-苯甲酰硫基-2-甲基丙酰]-4-(苯硫基)-L-脯氨酸钙盐，具有以下结构：
• [EN] NOVEL CRYSTALLINE FORMS<br/>[FR] NOUVELLES FORMES CRISTALLINES
  申请人：GENERICS UK LTD

  公开号：WO2009106894A1

  公开（公告）日：2009-09-03

  The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.

  本发明涉及左非诺普利钙的两种新结晶形式，以及它们的制备过程和在药物组合物中的应用。
• [EN] NOVEL CRYSTALLINE FORM<br/>[FR] NOUVELLE FORME CRISTALLINE
  申请人：GENERICS UK LTD

  公开号：WO2009022168A1

  公开（公告）日：2009-02-19

  The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and the use of the new crystalline form and compositions in the treatment of hypertension and various other diseases.

  本发明涉及一种新的无水结晶形式的左氯普利钙，化学式为(I)，化学上称为(4S)-1-[(2S)-3-(苯甲酰硫基)-2-甲基丙酰基]-4-(苯硫基)-L-脯氨酸钙盐或半钙盐。本发明还涉及左氯普利钙新晶型的制备方法，其在药物组合物中的使用以及新晶型和组合物在治疗高血压和各种其他疾病中的使用。
• Novel Crystalline Compounds
  申请人：Gore Vinayak G.

  公开号：US20080182888A1

  公开（公告）日：2008-07-31

  The present invention relates to a novel crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium and its use in pharmaceutical preparations.

  本发明涉及一种新的晶态形式的左氧氟沙利钙，化学式为(I)，化学名称为(4S)-1-[(2S)-3-(苯甲酰硫基)-2-甲基丙酰基]-4-(苯硫基)-L-脯氨酸钙盐。本发明还涉及一种制备新的左氧氟沙利钙晶态的方法以及其在药物制剂中的应用。
• Process for the preparation of zofenopril calcium salt
  申请人：MENARI RICERCHE S.P.A.

  公开号：US20020156293A1

  公开（公告）日：2002-10-24

  A process for the preparation of polymorph A of zofenopril calcium salt in substantially pure form, which comprises: 1) reaction of S(-)-3-benzoylthio-2-methylpropanoic acid chloride with cis-4-phenylthio-L-proline in water at pH ranging from 9.0 to 9.5 and recovery of zofenopril in the acidic form; b) salification of acid zofenopril with a potassium salt in alcoholic solution, and recovery of the resulting potassium salt; c) conversion of the potassium salt to the calcium salt by addition of zofenopril potassium salt aqueous solution to a CaCl 2 aqueous solution at a temperature of 70-90° C. with simultaneous seeding to promote the precipitation of polymorph A.

  一种制备纯度较高的左旋扎鲁普利钙盐A多晶形的方法，包括以下步骤：1）在pH值在9.0至9.5的水中反应S（-）-3-苯甲酰硫基-2-甲基丙酸氯化物和顺式-4-苯硫基-L-脯氨酸，并以酸性形式回收扎鲁普利；2）将酸性扎鲁普利与醇溶液中的钾盐盐化，回收所得的钾盐；3）将钾盐转化为钙盐，方法是将扎鲁普利钾盐水溶液加入到70-90°C的CaCl2水溶液中，并同时加入种晶剂以促进A多晶形的沉淀。